Study identifier:5077IL/0115
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Exploratory, Multicentre, Double-blind, Double-dummy, Randomised, Parallel-group, Controlled Phase III Study to Evaluate the Safety and Tolerability of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) in Treatment of Elderly Subjects with Alzheimers Disease with Symptoms of Psychosis and/or Agitation Compared to Seroquel Immediate Release Formulation.
schizophrenia
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|